3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Advanced Cancer
1
Interventions
pembrolizumab
26
Gemcitabine
20
Cisplatin
12
Nivolumab
11
Carboplatin
8
Paclitaxel
7
Docetaxel
7
atezolizumab
6
durvalumab
5
Radiotherapy
5
fludarabine
4
enfortumab vedotin
4
Ipilimumab
4
Cyclophosphamide
4
Vorinostat
3
Magnetic Resonance Spectroscopy
3
Fluorouracil
3
Filgrastim
3
Doxorubicin
3
zimberelimab
2
vocimagene amiretrorepvec
2
tremelimumab
2
romidepsin
2
poly ICLC
2
infigratinib
2
erdafitinib
2
cc-486
2
belinostat
2
avelumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Urinary Bladder Neoplasms
×
lirilumab
×
Clear all
NCT03532451
2024-09-19
PrE0807
PrECOG, LLC.
Phase 1
Completed
43 enrolled
15 charts